Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Liabilities and Shareholders Equity: 2023-2025

Historic Liabilities and Shareholders Equity for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $459.8 million.

  • Monte Rosa Therapeutics' Liabilities and Shareholders Equity rose 45.94% to $459.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 34.29%. This contributed to the annual value of $438.7 million for FY2024, which is 44.44% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Liabilities and Shareholders Equity stood at $459.8 million, which was up 27.88% from $359.6 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $459.8 million for Q3 2025, and its period low was $252.1 million during Q3 2023.
  • Its 3-year average for Liabilities and Shareholders Equity is $338.3 million, with a median of $315.1 million in 2024.
  • Per our database at Business Quant, Monte Rosa Therapeutics' Liabilities and Shareholders Equity fell by 13.68% in 2024 and then surged by 47.41% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $303.8 million in 2023, then soared by 44.44% to $438.7 million in 2024, then soared by 45.94% to $459.8 million in 2025.
  • Its last three reported values are $459.8 million in Q3 2025, $359.6 million for Q2 2025, and $393.2 million during Q1 2025.